Sugi Predict

Sugi Predict / Compounds / SCHEMBL16679332

SCHEMBL16679332

SCHEMBL16679332

Cn1cc(-c2cnc(N)c(Br)c2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 3/20 0.55
▸ MAP4K4 O95819 1/20 0.49
▸ IKBKE Q14164 1/20 0.48
▸ TBK1 Q9UHD2 1/20 0.48
▸ MET P08581 10/20 0.47
▸ AURKA O14965 1/20 0.44
▸ TTK P33981 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ INCENP Q9NQS7 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ FGFR1 P11362 1/20 0.43
▸ FGFR2 P21802 1/20 0.43
▸ FGFR3 P22607 1/20 0.43
▸ MKNK1 Q9BUB5 1/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41
▸ PIK3CD O00329 1/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ PIK3CB P42338 1/20 0.41
▸ PI4KA P42356 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30388097 0.89 LRRK2 (0.45) LRRK2MAP4K4IKBKETBK1MET
SCHEMBL21776551 0.89 LRRK2 (0.45) LRRK2MAP4K4IKBKETBK1MET
SCHEMBL21779385 0.81 LRRK2 (0.60) LRRK2MAP4K4IKBKETBK1MET
SCHEMBL21557014 0.80 LRRK2 (0.55) LRRK2MAP4K4IKBKETBK1MET
SCHEMBL30519642 0.80 MAP4K4 (0.43) LRRK2MAP4K4IKBKETBK1MET
SCHEMBL21776574 0.80 LRRK2 (0.58) LRRK2IKBKETBK1METHTT
SCHEMBL30388106 0.80 LRRK2 (0.58) LRRK2IKBKETBK1METHTT
SCHEMBL30388408 0.78 MET (0.55) IKBKETBK1METFGFR1FGFR2
SCHEMBL21776509 0.78 MET (0.55) IKBKETBK1METFGFR1FGFR2
SCHEMBL31285511 0.78 IKBKE (0.44) LRRK2IKBKETBK1METTTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024254536-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS, INC. (US) 2024-12-12 — — WO disclosed
EP-3365335-B1 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES ARRAY BIOPHARMA INC (US) 2024-02-14 — — EP disclosed
CN-113195471-B Polysubstituted pyridone derivative and application thereof in medicine 苏州浦合医药科技有限公司 2023-05-02 — — CN disclosed
US-20210355107-A1 MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD (CN) 2021-11-18 — — US disclosed
US-20210355107-A1 MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD (CN) 2021-11-18 — — US disclosed
CN-113195471-A Polysubstituted pyridone derivative and application thereof in medicine 北京越之康泰生物医药科技有限公司 2021-07-30 — — CN disclosed
EP-3845527-A1 MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF Beijing Yuezhikangtai Biomedicines Co., Ltd. (CN) 2021-07-07 — — EP disclosed
US-10766881-B2 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases ARRAY BIOPHARMA INC. (US) 2020-09-08 — — US disclosed
US-10766881-B2 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases ARRAY BIOPHARMA INC. (US) 2020-09-08 — — US disclosed
US-10660888-B2 Aminoheteroaryl benzamides as kinase inhibitors NOVARTIS AG (CH) 2020-05-26 — — US disclosed
WO-2017070708-A1 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES ARRAY BIOPHARMA, INC. (US) 2017-04-27 — — WO disclosed
WO-2017070708-A1 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES ARRAY BIOPHARMA, INC. (US) 2017-04-27 — — WO disclosed
EP-3063143-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS Novartis AG (CH) 2016-09-07 — — EP disclosed
US-9242996-B2 Aminoheteroaryl benzamides as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
US-9242996-B2 Aminoheteroaryl benzamides as kinase inhibitors NOVARTIS AG (CH) 2016-01-26 — — US disclosed
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — US disclosed
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — US disclosed
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — US disclosed
WO-2015066188-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — WO disclosed
WO-2015066188-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS AG (CH) 2015-05-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150126490-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS ABL1, MAP3K12, MAP3K2 LRRK2 620/4885MAP4K4 23/4885IKBKE 289/4885
US-20210355107-A1 MULTI-SUBSTITUTED PYRIDONE DERIVATIVES AND MEDICAL USE THEREOF PDXK, ITK, JAK1 LRRK2 1277/4885MAP4K4 205/4885IKBKE 1100/4885
US-10766881-B2 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases FGFR1, FGFR2, FGFR3 LRRK2 108/4885MAP4K4 147/4885IKBKE 256/4885
US-10660888-B2 Aminoheteroaryl benzamides as kinase inhibitors ABL1, MAP3K12, MAP3K2 LRRK2 620/4885MAP4K4 23/4885IKBKE 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.